Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis, Dermatology, Dermatology, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/29/2018 |
| Start Date: | July 2, 2018 |
| End Date: | August 8, 2018 |
Assessing Caregiver's Confidence in the Use of Topical Corticosteroids for a Child's Atopic Dermatitis
In dermatology, topical anti-inflammatory medications, such as corticosteroids, are the
mainstay treatment of managing patients with atopic dermatitis. However, caregivers are often
apprehensive about choosing a topical steroid for a variety of reasons. Many caregivers are
not aware that clinical trial evidence for these medications exist, and instead may rely on
anecdotal evidence in choosing to take these medications. Because fear of the drug is
inherently subjective, it can be modified with appropriate reassurance and presentation of
evidence. The goal of the study is to learn whether caregivers are more confident in treating
a child's atopic dermatitis after being presented with varying amounts of information.
mainstay treatment of managing patients with atopic dermatitis. However, caregivers are often
apprehensive about choosing a topical steroid for a variety of reasons. Many caregivers are
not aware that clinical trial evidence for these medications exist, and instead may rely on
anecdotal evidence in choosing to take these medications. Because fear of the drug is
inherently subjective, it can be modified with appropriate reassurance and presentation of
evidence. The goal of the study is to learn whether caregivers are more confident in treating
a child's atopic dermatitis after being presented with varying amounts of information.
Atopic dermatitis is the most common chronic, inflammatory dermatologic condition in young
children, with a prevalence approaching 25% in some countries. Topical corticosteroids, the
mainstay treatment in managing atopic dermatitis, generally function to decrease inflammation
and suppress the immune response. Topical corticosteroids are grouped into distinct
categories based on their degree of potency, including very high potency (Clobetasol
propionate), high potency (triamcinolone acetonide), medium potency (fluocinonide), and low
potency agents (desonide).
Caregivers are often apprehensive about choosing a topical steroid for a variety of reasons.
These include hearing negative information about the drug from friends or family, being
nervous about treatment, or seeing the drug or its side effects negatively portrayed in the
media. Many parents/caregivers are not aware that clinical trial evidence for these
medications exist, and instead may rely on anecdotal evidence in choosing to take these
medications.
Because fear of the drug is inherently subjective, it can be modified with appropriate
reassurance and presentation of evidence. By understanding what kind of information will
allow caregivers to be confident in their decision to use a topical corticosteroid,
dermatologists may improve treatment adherence and outcomes. The goal of the study is to
learn whether caregivers are more confident in treating a child's atopic dermatitis after
being presented with varying amounts of information about the treatment.
children, with a prevalence approaching 25% in some countries. Topical corticosteroids, the
mainstay treatment in managing atopic dermatitis, generally function to decrease inflammation
and suppress the immune response. Topical corticosteroids are grouped into distinct
categories based on their degree of potency, including very high potency (Clobetasol
propionate), high potency (triamcinolone acetonide), medium potency (fluocinonide), and low
potency agents (desonide).
Caregivers are often apprehensive about choosing a topical steroid for a variety of reasons.
These include hearing negative information about the drug from friends or family, being
nervous about treatment, or seeing the drug or its side effects negatively portrayed in the
media. Many parents/caregivers are not aware that clinical trial evidence for these
medications exist, and instead may rely on anecdotal evidence in choosing to take these
medications.
Because fear of the drug is inherently subjective, it can be modified with appropriate
reassurance and presentation of evidence. By understanding what kind of information will
allow caregivers to be confident in their decision to use a topical corticosteroid,
dermatologists may improve treatment adherence and outcomes. The goal of the study is to
learn whether caregivers are more confident in treating a child's atopic dermatitis after
being presented with varying amounts of information about the treatment.
Inclusion Criteria:
- Parent/Caregiver of an individual age <1-17 years old
- Subjects with a working knowledge of English
Exclusion Criteria:
- Parent/Caregiver of an individual 18 years or older
We found this trial at
1
site
Click here to add this to my saved trials
